scholarly journals Serum Lipids, Cholesterol, α-Tocopherol, and Retinol in Multiple Sclerosis Patients before and after Hyperbaric Oxygen Therapy

1988 ◽  
Vol 5 (1) ◽  
pp. 87-91 ◽  
Author(s):  
Keb GHEBREMESKEL ◽  
Glynne WILLIAMS ◽  
Laurence S. HARBIGE
Keyword(s):  
Multiple Sclerosis ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Serum Lipids ◽  
Oxygen Therapy ◽  
Before And After ◽  
Multiple Sclerosis Patients

scholarly journals Hyperbaric Oxygen Therapy in the Treatment of Idiopathic Sudden Sensorineural Hearing Loss

2015 ◽  
Vol 23 (3) ◽  
pp. 87-91
Author(s):  
Debashish Guha ◽  
Shaoni Sanyal ◽  
Chayan Bhattacharya ◽  
Abhijit Santra ◽  
Swagatam Banerjee
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Clinical Feature ◽  
Tertiary Referral Hospital ◽  
Before And After

Backgrounds and objectivesIdiopathic sudden sensorineural hearing loss (ISSNHL) is an entity whose diagnosis and treatment remain controversial to date. Various modalities of treatment have been tried with varying degrees of success. Hyperbaric oxygen therapy (HBOT) is a recent modality of treatment for this condition which acts by improving cochlear microcirculation. The objective of this study was to evaluate the effect of HBOT in improving hearing loss and secondary symptoms patients with ISSNHL.MethodsThis prospective study was undertaken over a 6 month period from the Department of Otorhinolaryngology in a tertiary referral hospital in eastern India. 48 consecutive newly diagnosed ISSNHL patients were included in this study. The patients were subjected to HBOT at 2 A.T.A (Atmosphere Absolute) for an hour over 45 days. Hearing status and secondary symptoms as assessed by clinical tests, pure tone audiogram were analysed before and after HBOT.ResultsMales comprised 62.5% (30/48) of our study population, mean age of the population was 49.3 ± 13.4 years. 45/48 patients (93.7%) had unilateral ISSNHL, while 3 (6.3%) had bilateral ISSNHL. Average hearing loss in the affected ear before and after treatment was 79.96dBHL and 62.27dBHL respectively. The most common secondary clinical feature was tinnitus (27/48, 56.3%), followed by vertigo (24/48, 50%), aural fullness (15/48, 31.25%) and nystagmus (5/48, 10.41%). After treatment tinnitus and vertigo were showed marked improvement; (22/27, 81.48%) and (18/24, 75%). 5 out of 15 (33.34%) patients showed reduced aural fullness. There was no improvement in patients suffering from nystagmus.

scholarly journals Chronic fatigue syndrome and epigenetics: The case for hyperbaric oxygen therapy in biomarker identification

2021 ◽  
Vol 5 (1) ◽  
pp. 027-030
Author(s):  
Shah Rajit J
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Hyperbaric Oxygen ◽  
Treatment Option ◽  
Epigenetic Regulation ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Chronic Fatigue ◽  
Hypoxic Conditions ◽  
Fatigue Syndrome ◽  
Before And After

Chronic fatigue syndrome (CFS) is a poorly-understood respiratory condition that affects millions of individuals. Hyperbaric oxygen therapy (HBOT) is a treatment option being considered to address CFS as it is suggested to combat fatigue and increase oxygenation. HBOT provides two opportunities in advancing research of CFS: it may provide data on symptom amelioration and be utilized in the search for a biomarker. By either identifying biomarkers before using HBOT to compare epigenomes of patients before and after treatment or using HBOT to find epigenetic discrepancies between patients with and without treatment, matching epigenetic regulation with symptom amelioration may significantly advance the understanding of the etiology and treatment mechanism for CFS. EPAS1/HIF-2α is a leading candidate for an epigenetic biomarker as it responds differentially to hypoxic and normoxic conditions, which degrades more slowly in hypoxic conditions. Epigenetic regulation of EPAS1/HIF-2α in such differential conditions may be explored in HBOT experiments. In addition to HBOT as a promising treatment option for CFS symptoms, it may aid the identification of biomarkers in CFS. Further research into both outcomes is strongly encouraged.

scholarly journals The THE DIFFERENCE OF PHYSICAL DIMENSION IN THE QUALITY OF LIVING ON PATIENTS OF DIABETES MELLITUS BETWEEN GIVING HYPERBARIC OXYGEN THERAPY 10 DAYS AND 5 DAYS

2019 ◽  
Vol 2 (03) ◽  
pp. 296-303
Author(s):  
Mufarika Mufarika ◽  
Siti Aminah
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
T Test ◽  
Control Group ◽  
Before And After ◽  
Paired T Test

ABSTRACT   Quality of life is the subjective perception of the individual to the physical, psychological, social, and environmental conditions experienced. The aim of the study was to analyze differences in the physical dimensions of the quality of life of diabetes mellitus patients between providing hyperbaric oxygen therapy 10 days and 5 days. This study used the quasy experiment method with the approach of pre post test with control group design. The population in the study was 882 people with a sample of 14 respondents divided into two groups. 7 respondents in the treatment group and 7 respondents in the control group. Sampling used was consecutive sampling technique. Data were analyzed using Paired t test and Independent t test. The results of the Paired t test statistic in the treatment group had differences in quality of life before and after 10 days of hyperbaric oxygen therapy, while the control group had no difference in quality of life before and after 5 days of hyperbaric oxygen therapy. The independent t test results were different after being given hyperbaric oxygen therapy 10 days and 5 days. It is expected that health workers can be used as a reference source and as a basis for determining nursing intervention in the management of diabetes, especially in the quality of life of diabetic patients.

Sign in / Sign up

Export Citation Format

Share Document